Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma
Open Access
- 28 January 2026
- journal article
- Published by Springer Nature in Cell Discovery
- Vol. 12 (1) , 8
Abstract
Deeper insights into omics in the clinical and tumor microenvironments of lung adenocarcinoma (LUAD) could reveal therapy-sensitive subtypes and novel treatments. From a cohort of 1008 samples from Chinese patients with LUAD with whole-genome and transcriptome sequencing data along with comprehensive longitudinal clinical and therapeutic information, we identified four prognostically distinct subtypes, namely, low proliferation and invasion (LPI), immune-desert (IMD), immune-enriched (IME), and high proliferation and invasion (HPI), based on the transcriptomic features linked to the radiological, pathological, and microenvironmental dimensions. Compared with chemotherapy, tyrosine kinase inhibitor (TKI) therapy demonstrated significantly superior efficacy for LPI and IMD, whereas no such difference was observed for HPI. VOPP1 and RRM2B amplification were closely associated with TKI resistance and sensitivity, respectively. VOPP1 knockdown restored sensitivity to TKI treatment, while RRM2B knockdown induced TKI resistance, and its overexpression restored sensitivity. Patients with RRM2B amplification had a 5-year survival rate of nearly 100%. Additionally, the IME subtype exhibited higher immune checkpoint activity and a higher frequency of DYNC2H1 mutation, with patients benefiting from immunotherapy. These findings provide critical insights into LUAD treatment optimization.Keywords
Funding Information
- National Natural Science Foundation of China (82430099)
- National Natural Science Foundation of China (82203037)
- State Sponsored Postdoctoral Fellowship Programme
This publication has 99 references indexed in Scilit:
- Activated fibroblasts in cancer: Perspectives and challengesCancer Cell, 2023
- The evolving tumor microenvironment: From cancer initiation to metastatic outgrowthCancer Cell, 2023
- Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomesCancer Cell, 2022
- Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the USJAMA Oncology, 2021
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Lung Cancer Screening with Low-Dose CT: Baseline Screening Results in ShanghaiAcademic Radiology, 2019
- Genomic Features of Response to Combination Immunotherapy in Lung CancerCancer Cell, 2018
- Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunitiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2017
- ascatNgs: Identifying Somatically Acquired Copy‐Number Alterations from Whole‐Genome Sequencing DataCurrent Protocols in Bioinformatics, 2016
- Novel regulators and molecular mechanisms of p53R2 and its disease relevanceBiochimie, 2016